S. Korea Ministry Agrees With Drug Industry To End Kickback Practice
This article was originally published in PharmAsia News
South Korea has launched a drive to end the practice of drug makers providing kickbacks to physicians and pharmacists. The Ministry for Health, Welfare and Family Affairs said wholesalers of all types who receive such rewards are to be sanctioned along with those who provide them. The pharmaceutical industry favored the legislation that called for the sanctions because it wanted to end the vicious circle of bribes. The Korea Pharmaceutical Manufacturers Association has proposed taking the money its members otherwise would have to pay doctors and pharmacists and invest it into research and development. The health ministry accepted the proposal. (Click here for more
You may also be interested in...
Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.